248 related articles for article (PubMed ID: 12036427)
1. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Herbst RS
Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427
[TBL] [Abstract][Full Text] [Related]
2. ZD1839 (Iressa): for more than just non-small cell lung cancer.
Ranson M
Oncologist; 2002; 7 Suppl 4():16-24. PubMed ID: 12202784
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
Penne K; Bohlin C; Schneider S; Allen D
Cancer Nurs; 2005; 28(6):481-6. PubMed ID: 16330971
[TBL] [Abstract][Full Text] [Related]
4. ZD1839 ('Iressa') as an anticancer agent.
Baselga J; Averbuch SD
Drugs; 2000; 60 Suppl 1():33-40; discussion 41-2. PubMed ID: 11129170
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.
Albanell J; Rojo F; Baselga J
Semin Oncol; 2001 Oct; 28(5 Suppl 16):56-66. PubMed ID: 11706397
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
[TBL] [Abstract][Full Text] [Related]
8. The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.
Al-Hazzaa A; Bowen ID; Randerson P; Birchall MA
Cell Prolif; 2005 Apr; 38(2):77-86. PubMed ID: 15842252
[TBL] [Abstract][Full Text] [Related]
9. Phase I studies of ZD1839 in patients with common solid tumors.
Lorusso PM
Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
[TBL] [Abstract][Full Text] [Related]
10. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
Magné N; Fischel JL; Dubreuil A; Formento P; Poupon MF; Laurent-Puig P; Milano G
Br J Cancer; 2002 May; 86(9):1518-23. PubMed ID: 11986789
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
12. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
13. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
[TBL] [Abstract][Full Text] [Related]
14. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
15. The role of EGFR-directed therapy in the treatment of breast cancer.
Morris C
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S51-5; discussion S57-9. PubMed ID: 12353824
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
[TBL] [Abstract][Full Text] [Related]
19. ZD1839 (Iressa): what's in it for the patient?
Natale RB; Zaretsky SL
Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785
[TBL] [Abstract][Full Text] [Related]
20. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Janmaat ML; Giaccone G
Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
